Abstract：Objective To explore the clinical effect of Sacubatrol Valsartan Sodium in the treatment of heart failure with preserved ejection fraction (HFpEF). Methods A total of 78 patients with HFpEF admitted to our hospital from March 2018 to May 2019 were enrolled as study subjects. The participants were divided into the control group (n=39) and the experimental group (n=39) according to the random number table method. The control group was given routine treatment, while the experimental group was given Sacubatrol Valsartan Sodium. The therapeutic effect, cardiac function indexes (early diastolic velocity of mitral valve [E], early diastolic velocity of mitral annulus [e′], E/peak diastolic velocity of mitral valve [E/A], E/e′), N-terminal B-type natriuretic peptide (NT-proBNP), 6 min walking test distance (6MWT),quality of life score before and after treatment and incidence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group was 92.31%, which was higher than that in the control group accounting for 79.49%, with statistical difference (P＜0.05). There were no significant differences in cardiac function indexes, NT-proBNP, 6MWT and quality of life score between the two groups before treatment (P＞0.05). The E, e′ and E/A of the two groups after treatment were higher than those before treatment, the 6MWT was farther than that before treatment, with statistical differences (P＜0.05). The E/e′, NT-proBNP and quality of life scores in the two groups after treatment were lower than those before treatment, with statistical differences (P＜0.05). The E, e′and E/A in the experimental group after treatment were higher than those in the control group, the 6MWT was farther than that in the control group, with statistical differences (P＜0.05). The E/e′, NT-proBNP and quality of life scores in the experimental group after treatment were lower than those in the control group, with statistical differences (P＜0.05). There was no significant difference in the total incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion The effect of Sacubatrol Valsartan Sodium is remarkable in the treatment of HFpEF. It can enhance cardiac function, and increase the exercise tolerance and quality of life in patients of HFpEF without increasing the incidence rate of adverse reaction, whcih is worthy of clinical application.
Huang W，Chai SC，Lee SGS，et al.Prognostic factors after index hospitalization for heart failure with preserved ejection fraction[J].Am J Cardoil，2017，119（12）：2017-2020.
[3]
Suematsu Y，Jing W，Nunes A，et al.LCZ696 （Sacubitril/valsartan），an angiotensin-receptor neprilysin inhibitor，attenuates cardiac dypertrophy，fibrosis and vasculopathy in a rat model of chronic kidney disease[J].J Card Fail，2018，24（4）：266-275.
Bittner V，Weiner DH，Yusuf S，et al.Prediction of mortality and morbidity with 6-minute walk test in patients with left ventricular dysfunction[J].JAMA，1993，270（14）：1702-1707.
[8]
Rector TS，Cohn JN.Assessment of patient outcome with the minnesota living with heart failure questionnaire：reliability and validity during a randomized，double-blind，placebocontrolled trial of pimobendan[J].Am Heart J，1992，124（4）：1017-1025.
Rodgers JE.Sacubitril/Valsartan：The newest addition to the toolbox for guideline-directed medical therapy of heart failure[J].Am J Med，2017，130（6）：635-639.
Wang Y，Gu X，Fan W，et al.Effects of recombinant human brain natriuretic peptide on renal function in patients with acute heart failure following myocardial infarction[J].Am J Transl Res，2016，8（1）：239-245.
[13]
Chen CH.Critical questions about PAR-ADIGM-HF and the future[J].Acta Cardiol Sin，2016，32（4）：387-396.
[14]
Von Lueder TG，Sangaralionham SJ，Wang BH，et al.Renin-angiotensin blockade combined with natriuretic peptide system augmentation：novel therapeutic concepts to combat heart failure[J].Circ Heart Fail，2013，6（3）：594-605.
Solomon SD，Claggett B，Desai AS，et al.Influence of ejection fraction on outcomes and efficacy of Sacubitril/Valsartan （LCZ696） in heart failure with reduced ejection fraction Clinical perspective[J].Circ Heart Fail，2016，9（3）：e002744.
京公网安备 11010502046607号